Ivonescimab combined with chemotherapy for locally advanced or metastatic NSCLC resistant to EGFR-TKI therapy, which has now been approved for marketing in China and added to China's National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback